AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT01651351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Alpha1-proteinase inhibitor
Description: GLASSIA will be supplied as a sterile, non-pyrogenic, ready-to-use solution, in single dose 50 mL vials; for intravenous administration.
Study NCT01651351 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Placebo: Human albumin 2.5%
Description: Intravenous administration
Study NCT04254068 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Parent-based prevention
Description: Parent-based prevention is a 12 session program for parents with eating disorders and their partners. Most sessions occur on a weekly basis, most of the sessions involve both partners.
Study NCT00362349 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IgNextGen 10%
Description: Ig NextGen 10% is a liquid formulation and is to be administered intravenously. At the discretion of the Investigator, patients could be administered Ig NextGen 10% in accordance with either of two dosage regimens:~Regimen One: 1 g/kg body weight of Ig NextGen 10% administered daily for two days.~Regimen Two: 0.4 g/kg body weight of Ig NextGen 10% administered daily for five days
Study NCT00679510 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: rosuvastatin
Description: tablet 10 mgs once daily
Study NCT00679510 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: placebo
Study NCT03944226 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Beetroot juice
Description: The patient will follow a 5 day dietary nitrate intervention programme, taking 3 doses of 7cl (0.4 g nitrate per dose) concentrated beetroot juice (SPORT shot, James White Drinks, Suffolk, U.K.) a day.
Study NCT02403336 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training health professionals
Description: Intervention on the professionals (3 training sessions for updating the knowledge and learning skills) and
Study NCT02403336 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Behavioral group intervention
Description: Intervention on patients (educational workshop).
Study NCT02403336 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual clinical practice
Description: Professionals: meeting methodological of 30 minutes duration. Patients: Usual clinical practice. Health education individually on nursing consultation.
Study NCT03890783 — intervention group
Intervention type: OTHER
Intervention: Evaluation of phonation quality
Description: Evaluation of phonation quality by :~* Self-evaluation: completion of the Voice Handicap Index questionnaire, in its 30 items version~* Hetero-evaluation: reading and recording of 2 texts, and notation by 3 practitioners using the grade, rough, breathy, asthenic, strained (GRBAS) scale, to evaluate the occurrence and the gravity of rhinolalia
Study NCT03890783 — intervention group
Intervention type: OTHER
Intervention: Evaluation of swallowing quality
Description: Evaluation of swallowing quality by:~* Self-evaluation: completion of the Deglutition Handicap Index questionnaire~* Hetero-evaluation: nasofibroscopy to evaluate the occurrence of aspiration and nasal regurgitation
Study NCT03890783 — intervention group
Intervention type: OTHER
Intervention: global quality of life questionnaire
Description: Completion of the European Organization for Research and Treatment of Cancer Quality of Life questionnaire (EORTC QLQ - C30) and the EORTC QLQ - H\&N35 questionnaires
Study NCT03525717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Routine Dinner
Description: Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
Study NCT03525717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Routine Dinner
Description: Participants will be served dinner at a routine time (18:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
Study NCT03525717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Late dinner
Description: Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
Study NCT03525717 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Late dinner
Description: Participants will be served dinner at a late time (22:00), along with with a stable isotope of palmitate to measure fat oxidation overnight.
Study NCT00708149 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lansoprazole OD
Description: arm 1: lansprazole 30 mg qd from NG route or orally for 14 days
Study NCT00708149 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: takepron placebo
Study NCT01786603 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rasagiline
Description: Rasagiline 2mg once a day for 12 months.
Study NCT01786603 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo (looks like study drug but has no active ingredients) once a day for 12 months.
Study NCT04071743 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: gammaCore Sapphire
Description: non-invasive vagus nerve stimulator
Study NCT04071743 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham gammaCore Sapphire
Description: sham gammaCore Sapphire
Study NCT03173729 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: Biosensor Point of Care Device
Description: This device is a point of care urine-based metabolomic diagnostic test that detects metabolite biomarkers for CRC and polyps.
Study NCT03096951 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Prehabilitation
Description: Prehabilitation group will receive a 4-week tele-supervised prehabilitation and a 8-week tele-supervised postoperative rehabilitation.
Study NCT03096951 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Rehabilitation
Description: Rehabilitation group will receive World Health Organization recommendations on physical activity for health before surgery and a 8-week tele-supervised postoperative rehabilitation.
Study NCT02997735 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Quitline Delivered Treatment
Description: The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
Study NCT02997735 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Quitline Delivered Treatment
Description: The PA Free quitline is funded by the Pennsylvania Department of Health and staffed by trained cessation counselors available 24 hours a day, 7 days a week. Counseling is available in English and Spanish and can be provided in at least 15 additional languages through a third party. All smokers who enroll in smoking cessation treatment will receive counseling and support consistent with accepted clinical practice guidelines. This treatment includes as many as 5 proactive counseling calls, each designed to help develop problem-solving and coping skills, secure social support, and plan for long-term abstinence. Participants can also call an 800 telephone number as needed for additional support between calls. The timing of counseling calls will be relapse sensitive and include a call 1-2 days after the quit date, another telephone call a week after the first call, and additional calls generally occurring at 2-3-week intervals thereafter.
Study NCT03025230 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dry needling and electric stimulation
Description: Dry needling technique and the application of electric stimulation of levator scapulae PG
Study NCT03025230 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Dry needling
Description: Treatment of PG with a filiform needle in levator scapulae muscle
Study NCT00927290 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pioglitazone
Description: Pioglitazone, 45 mg QD (30 mg QD the first month)
Study NCT00927290 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 45 mg QD (30 mg QD the first month)
Study NCT01547169 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator
Description: saline, taken twice per day for a 3 week duration
Study NCT01547169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: 10IU of insulin detemir, administered intranasally twice per day for a 3 week duration
Study NCT01547169 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: insulin detemir
Description: 20IU insulin detemir, administered intranasally twice per day for a 3 week duration
Study NCT00841568 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: OPC-41061
Description: orally administered at 15 mg twice daily (morning and evening) for a maximum of 3 years.
Study NCT03566355 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: curative proton therapy
Description: Patients who meet the selection criteria are selected, signed for consent, and treated with proton therapy alone at 7200 cGy / 15 fractions, 5 times a week for 3 weeks
Study NCT00670670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP (GC Tooth Mousse)
Description: Calcium and phosphate
Study NCT00670670 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: CPP-ACP (GC MI Paste Plus)
Description: Calcium, phosphate and fluoride
Study NCT01022242 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PXL01
Description: PXL01 is a synthetic peptide sequentially derived from human lactoferrin. PXL01 is formulated in a viscous solution of sodium hyaluronate. The drug product is administered locally between the flexor tendon and the tendon sheath and around the tendon sheath at a volume of 0.5 ml. Administration of the product is carried out after repair of the flexor tendon but before closure of the surgical wound.
Study NCT01022242 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo is a physiological sodium chloride solution, which is clear and colourless.
Study NCT03819348 — intervention group
Intervention type: OTHER
Intervention: the multiple programs of antifungal therapy for HIV-negative host
Description: the multiple programs of antifungal therapy for HIV-negative host TSM were compared in terms of effect on clinical remission rate, effective rate, recurrence rate, mortality and toxic side effects on HIV-negative host TSM; their prognosis and recurrence indicators were clarified, and a therapeutic effect evaluation system was established, providing a standard treatment and diagnosis scheme for clinical practice; and simultaneously the positive rate of G and GM experiments in respect of TSM, Aspergillus and other fungi was identified to provide TSM with biological diagnostic indicators.
Study NCT04178694 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: non-invasive ventilation
Description: non-invasive ventilation will be performed on every subjects
Study NCT00545727 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Diet
Description: Whole-foods, low glycemic index diet
Study NCT00545727 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Standard diet
Description: Standard diet meeting American Diabetes Association guidelines
Study NCT01556139 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Spirotiger
Description: The Training group perform 20 sessions of a specific training with Spirotiger, a device allowing respiratory muscle training with isocapnic hyperpnea.~The setting is the following:~* volume/size of the breathing bag: 50% of the vital capacity (VC) and ventilation (VE= Tidal volume x respiratory rate) at 66% of the MVV aiming to reach 15 minutes of training without breaks. During the initial sessions, the patient can interrupt training every 5 minutes and recover.~* increase in training: after 15 minutes of exercise VE is increased up to 75% of the MVV through modification of the volume of breathing bag or respiratory rate.~At the end of 15 minutes of exercise, further increases in ventilation are 10% of each previous step.
Study NCT04080947 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control group
Description: patients received matching-image placebo once daily at bedtime for 12 weeks.
Study NCT04080947 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Montelukast group
Description: patients received montelukast (10-mg chewable tablet) once daily at bedtime for 12 weeks.
Study NCT01820364 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LGX818
Description: BRAF inhibitor. LGX818 was administered QD orally on a daily schedule (21-day cycles) as a flat-fixed dose and not by body weight or body surface area. LGX818 100 mg capsules and 50 mg capsules.
Study NCT03418129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Mindfulness
Description: Neuromodulatory intervention for pain management
Study NCT03418129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neurofeedback
Description: Neuromodulatory intervention for pain management
Study NCT03418129 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Relaxation
Description: Neuromodulatory intervention for pain management
Study NCT00851539 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Video
Description: Behavioral Intervention Video
Study NCT04960982 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: blood test
Description: blood sample is taken in first, second and third trimester of pregnancy
Study NCT03300674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Hydromorphone
Description: Hydromorphone intravenous infusion
Study NCT03300674 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lidocaine
Description: Lidocaine intravenous infusion
Study NCT03755895 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: formal hypnosis
Description: patients will have brachytherapy detachment under Kalinox and formal hypnosis
Study NCT03755895 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Kalinox
Description: patients will have brachytherapy detachment under Kalinox
Study NCT03755895 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Kalinox
Description: patients will have brachytherapy detachment under Kalinox
Study NCT03521024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: poly ether ketone ketone
Description: Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
Study NCT03521024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: poly ether ketone ketone
Description: Polyetherketoneketone (PEKK) forms a group of high-performance thermoplastic polymers. PEKK shows excellent biocompatibility and exhibits outstanding properties such as high wear resistance and high compressive (246 MPa), flexural (5.0GPa), and tensile strengths (115 MPa). The material is lightweight, allows shock absorption, and can be veneered with various commercially available dental materials
Study NCT03521024 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: lithium disilicate
Description: well documented in the literatures as successful restoration modality.
Study NCT03521024 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: lithium disilicate
Description: well documented in the literatures as successful restoration modality.
Study NCT00547170 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Doxycycline pre-operatively
Description: Two capsules of Doxycycline 100 mg before vacuum aspiration Placebo 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
Study NCT00547170 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Doxycycline post-operatively
Description: Two capsules of placebo 100 mg before vacuum aspiration Doxycycline 100 mg twice daily for 5 days after vacuum aspiration (appearance of capsules is the same for both groups)
Study NCT02032563 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Indocyanine Green
Description: intravenous injection of 0.25mg/kg Indocyanine Green just before the surgery
Study NCT02227602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Mango polyphenolics
Description: Frozen mango pack will be provided (200\~400g per day).
Study NCT00788281 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery
Description: surgery would be performed by laparoscope
Study NCT00788281 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: open surgery
Description: surgery would be performed by traditional surgery.
Study NCT02198703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Probiotics bacterial strains
Study NCT02198703 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT04159220 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Clamping of the ventilator endotracheal tube
Description: The transport will be released in accordance with SFAR SRLF guideline. Before each disconnection from ventilator endotracheal tube will be clamped.
Study NCT04918199 — intervention group
Intervention type: DEVICE
Intervention: Computer based assessment (iBox)
Description: Individual allograft survival probabilities of death censored allograft survival seven years after the time of risk evaluation, computed using the iBox (NCT03474003), a qualified prognostication system designed to predict long term allograft survival up to seven years after evaluation.
Study NCT04918199 — intervention group
Intervention type: OTHER
Intervention: Physician assessement
Description: Based on anonymized electronic health records, physicians have to determine a percentage of death censored allograft survival seven years after the time of risk evaluation,
Study NCT03295370 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electrical Stimulation
Description: A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
Study NCT03295370 — intervention group
Intervention type: PROCEDURE
Group type: SHAM_COMPARATOR
Intervention: Electrical Stimulation
Description: A needle is placed near accessory spinal nerve; electrical burst stimulation for 12 minutes, 10 Hz;
Study NCT01651624 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Invitation to screening
Study NCT01651624 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Invitation to screening
Study NCT00841789 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etanercept
Description: etanercept 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
Study NCT00841789 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo 0.8 mg/kg subcutaneously (max 50 mg) given three times, once a week for three weeks starting at initial diagnosis.
Study NCT01857284 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tauroursodeoxycholic Acid Capsules
Description: 250mg.tid.po
Study NCT01857284 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ursodeoxycholic Acid Capsules
Description: 250mg.tid.po
Study NCT00825162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Virus Vaccine
Description: Single or two-vaccination regimen (0.25mL)
Study NCT00825162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Virus Vaccine
Description: Single or two-vaccination regimen (0.5mL)
Study NCT00825162 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: CSL Limited Influenza Virus Vaccine
Description: Single vaccination regimen (0.5mL)
Study NCT04443543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Capecitabine (Xeloda) Pharmacogenetic Test Reagents
Description: CRT: 625mg/m2 bid Monday-Friday per week XELIRI: 1000mg/m2 bid d1-14
Study NCT04443543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: irinotecan
Description: CRT:80mg/m2 (UGT1A1\*28 6/6) or 65mg/m2 (UGT1A1\*28 6/7) XELIRI: 200mg/m2 bid d1 FOLFIRINOX: 150mg/m2 d1
Study NCT04443543 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: IMRT
Description: Pelvic Radiation: 50Gy/25Fx
Study NCT04443543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: FOLFIRINOX: 85mg/m2 d1
Study NCT04443543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5Fluorouracil
Description: FOLFIRINOX: 400mg/m2 iv d1bolus, 2400mg/m2 ivgtt 46h
Study NCT04443543 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tislelizumab
Description: 200mg iv